{
  "source": "PA-Med-Nec-Sovaldi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2053-19\nProgram Prior Authorization/Medical Necessity\nMedication Sovaldi® (sofosbuvir)\nP&T Approval Date 4/2015, 8/2015, 11/2015, 8/2016, 12/2016, 9/2017, 11/2018, 2/2019,\n3/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nSovaldi® (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor\nindicated for the treatment of:\n• Adult patients with genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection without\ncirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment\nregimen.\n• Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without\ncirrhosis or with compensated cirrhosis in combination with ribavirin.\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1 or 4 infection in peginterferon eligible\npatients who are without cirrhosis or have compensated cirrhosis, Sovaldi in combination\nwith peginterferon alfa and ribavirin will be approved based on all of the following\ncriteria:\n1. One of the following:\na. Diagnosis of chronic hepatitis C genotype 1 infection\n-OR-\nb. Diagnosis of chronic hepatitis C genotype 4 infection\n-AND-\n2. Patient has not experienced failure with a previous treatment regimen that includes\nSovaldi\n-AND-\n3. Used in combination with peginterferon alfa and ribavirin\n-AND-\n4. One of the following:\n© 2025 United Healthcare Services, Inc.\n1\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n6. One of the following:\na. All of the following:\n(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir)\ntherapy\n-AND-\n(3) History of i",
    "ry of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir)\ntherapy\n-AND-\n(3) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)\ntherapy\n-AND-\n(4) History of intolerance or contraindication to Zepatier (elbasvir/grazoprevir)\ntherapy\n-OR-\nb. Patient is currently on Sovaldi therapy\nAuthorization will be issued for 12 weeks.\nB. For the treatment of chronic hepatitis C genotype 1 infection who are without cirrhosis or\nhave compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based\non all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n© 2025 United Healthcare Services, Inc.\n2\n-AND-\n2. Patient has not experienced failure with a previous treatment regimen that includes\nSovaldi\n-AND-\n3. Used in combination with ribavirin\n-AND-\n4. Patient is ineligible for peginterferon alfa therapy\n-AND-\n5. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n7. One of the following:\na. All of the following:\n(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir)\ntherapy\n-AND-\n(3) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)\ntherapy\n© 2025 United Healthcare Services, Inc.\n3\n-AND-\n(4) History of intolerance or contraindication to Zepatier (elbasvir/grazoprevir)\ntherapy\n-OR-\nb. Patient is currently on Sovaldi therapy\nAuthorization will be issued for 24 weeks.\nC. For the treatment of chronic hepatitis C genotype 2 infection who are without cirrhosis or\nhave compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based\non a",
    "or 24 weeks.\nC. For the treatment of chronic hepatitis C genotype 2 infection who are without cirrhosis or\nhave compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based\non all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 2 infection\n-AND-\n2. Patient has not experienced failure with a previous treatment regimen that includes\nSovaldi\n-AND-\n3. Used in combination with ribavirin\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n6. One of the following:\na. Both of the following:\n(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\n© 2025 United Healthcare Services, Inc.\n4\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)\ntherapy\n-OR-\nb. Patient is currently on Sovaldi therapy\nAuthorization will be issued for 12 weeks.\nD. For the treatment of chronic hepatitis C genotype 3 infection who are without cirrhosis or\nhave compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based\non all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 3 infection\n-AND-\n2. Patient has not experienced failure with a previous treatment regimen that includes\nSovaldi\n-AND-\n3. Used in combination with ribavirin\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n6. One of the following:\n© 2025 United Healthcare Services, Inc.\n5\na. Both of the following:\n(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Mavyret (glec",
    "vices, Inc.\n5\na. Both of the following:\n(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)\ntherapy\n-AND-\n(2) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)\ntherapy\n-OR-\nb. Patient is currently on Sovaldi therapy\nAuthorization will be issued for 24 weeks.\nE. For the treatment of chronic hepatitis C genotype 1, 2, 3, or 4 infection in patients with\nhepatocellular carcinoma awaiting liver transplantation. Sovaldi in combination with\nribavirin will be approved based on all of the following criteria:\n1. Diagnosis of hepatocellular carcinoma\n-AND-\n2. Patient is an active candidate on the waiting list for a liver transplant\n-AND-\n3. Patient is being managed in a liver transplant center\n-AND-\n4. Patient has not experienced failure with a previous treatment regimen that includes\nSovaldi\n-AND-\n5. Used in combination with ribavirin\n-AND-\n6. Physician/provider asserts patient demonstrates treatment readiness, including the ability\nto adhere to the treatment regimen\n-AND-\n7. One of the following:\n© 2025 United Healthcare Services, Inc.\n6\na. Both of the following:\n(1) Diagnosis of chronic hepatitis C genotype 1or 4\n-AND-\n(2) One of the following:\n(a) Both of the following:\n• History of intolerance or contraindication to Harvoni\n(sofosbuvir/ledipasvir) therapy\n• History of intolerance or contraindication to Epclusa\n(sofosbuvir/velpatasvir) therapy\n-OR-\n(b) Patient is currently on Sovaldi therapy\n-OR-\nb. Both of the following:\n(1) Diagnosis of chronic hepatitis C genotype 2 or 3\n-AND-\n(2) One of the following:\n(a) History of intolerance or contraindication to Epclusa\n(sofosbuvir/velpatasvir) therapy\n-OR-\n(b) Patient is currently on Sovaldi therapy\nAuthorization will be issued for 48 weeks.\na. State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical ",
    "y federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply Limits may be in place.\n© 2025 United Healthcare Services, Inc.\n7\n4. References:\n1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttp://www.hcvguidelines.org/full-report-view. Accessed April 10, 2025.\nProgram Prior Authorization/Medical Necessity - Sovaldi (sofosbuvir)\nChange Control\n4/2015 Coverage requirements for State of New Jersey effective 5/18/15.\n8/2015 Added criteria for combination therapy with Daklinza (daclatasvir).\n11/2015 Revised criteria to remove Sovaldi plus ribavirin step for cirrhotic\npatients in section M, merged section N into M, changed program title to\ninclude all lines of business and updated language regarding\ndocumentation of liver fibrosis.\n7/2016 Added Indiana and West Virginia coverage information.\n8/2016 Updated criteria to include Eplcusa as well as revisions to peginterferon\neligibility requirements.\n10/2016 Administrative change to correct formatting.\n10/2016 Administrative change made for clarity.\n11/2016 Added California coverage information.\n12/2016 Removed abstinence-based criteria and replaced with treatment readiness\nscreening criteria.\n5/2017 Administrative update to reorder criteria. State mandate reference\nlanguage updated.\n9/2017 Revised step therapy criteria based on new product availability, included\nNY prescriber requirement, rem",
    "017 Administrative update to reorder criteria. State mandate reference\nlanguage updated.\n9/2017 Revised step therapy criteria based on new product availability, included\nNY prescriber requirement, removed treatment readiness screening tools\nand removed medical record submission requirements.\n11/2018 Annual review. Removed Olysio. Updated references.\n2/2019 Revised step therapy to include Zepatier for genotypes 1 & 4.\n3/2020 Annual review. Removed Daklinza as product is no longer available in\nmarket. Added requirement for peg-interferon ineligibility for genotype 1\n+ RBV. Removed Sovaldi + RBV for 24 weeks for GT 4 to align with\ncurrent label and recommendations.\n5/2021 Annual review. Removed prescriber requirement. Updated references.\n5/2022 Reformatted criteria. Updated references.\n5/2023 Annual review. Simplified peginterferon eligibility requirements.\nClarified generic names for Harvoni and Epclusa. Updated references.\n5/2024 Annual review. Removed liver disease staging criteria that was included\nfor quality purposes rather than part of coverage decision. Updated\nreferences.\n5/2025 Annual review without changes to coverage criteria. Updated references.\n© 2025 United Healthcare Services, Inc.\n8"
  ]
}